Publicaciones en las que colabora con María José García Sánchez (42)

2014

  1. Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients

    Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704

2013

  1. Nuevas estrategias en la optimización posológica de lopinavir/ritonavir en pacientes infectados por el virus de la inmunodeficiencia humana

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 1, pp. 36-43

2011

  1. Population pharmacokinetic/pharmacogenetic model for optimization of Efavirenz therapy in caucasian HIV-infected patients

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324

  2. Terapia personalizada en la infección por el VIH: Aplicación de criterios farmacogenéticos

    Anales de la Real Academia de Medicina y Cirugía de Valladolid, Núm. 48, pp. 75-99

2009

  1. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 7, pp. 2791-2798

  2. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis

    Clinical Pharmacokinetics, Vol. 48, Núm. 4, pp. 273-280

2008

  1. Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in german and spanish patients with epilepsy

    Therapeutic Drug Monitoring, Vol. 30, Núm. 4, pp. 483-489

2006

  1. Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions

    Clinical Microbiology and Infection, Vol. 12, Núm. SUPPL. 7, pp. 97-106

2005

  1. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies

    Antimicrobial Agents and Chemotherapy, Vol. 49, Núm. 12, pp. 4934-4941

2004

  1. Iniciación de un programa de monitorización de lamotrigina en pacientes epilépticos

    Atencion Farmaceutica, Vol. 6, Núm. 2, pp. 97-101

2001

  1. Farmacocinética de poblaciones: Una aproximación a la optimización del tratamiento con antimicrobianos

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 19, Núm. 5, pp. 219-228

1999

  1. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data

    Biopharmaceutics and Drug Disposition, Vol. 20, Núm. 5, pp. 233-240

  2. Valproate population pharmacokinetics in children

    Journal of Clinical Pharmacy and Therapeutics, Vol. 24, Núm. 1, pp. 73-80

1997

  1. Carbamazepine population pharmacokinetics in children: Mixed-effect models

    Therapeutic Drug Monitoring, Vol. 19, Núm. 2, pp. 132-139

  2. Population pharmacokinetics of caffeine in premature neonates

    European Journal of Clinical Pharmacology, Vol. 52, Núm. 3, pp. 211-217

1996

  1. Bayesian forecasting in paediatric populations

    Clinical Pharmacokinetics

1992

  1. Population pharmacokinetics of imipramine in children

    European Journal of Clinical Pharmacology, Vol. 43, Núm. 1, pp. 89-92

1991

  1. Effect of dose on the kinetic behaviour of valproic acid: modifications in plasma protein binding.

    European journal of drug metabolism and pharmacokinetics, Vol. Spec No 3, pp. 239-242

1989

  1. Predictive techniques applied to imipramine therapeutic drug monitoring

    DICP, Annals of Pharmacotherapy, Vol. 23, Núm. 5, pp. 389-394

1988

  1. Contribution of serum level monitoring in the individualization of carbamazepine dosage regimens

    International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 26, Núm. 8, pp. 409-412